SCHEMBL5337301

SCHEMBL5337301

Cc1nc(N)c2nc(CCC3CC3)n(CCOCCNC(=O)Nc3cccnc3)c2c1C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 3/20 0.40
NFE2L2 Q16236 3/20 0.40
CDK2 P24941 1/20 0.39
FLT4 P35916 1/20 0.39
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
PIK3CG P48736 3/20 0.34
PRMT3 O60678 2/20 0.34
EPHX2 P34913 1/20 0.34
CHRNA7 P36544 1/20 0.34
HTR1A P08908 1/20 0.33
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33
DRD3 P35462 1/20 0.33
CYP1A2 P05177 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5333512 0.93 KEAP1 (0.41) KEAP1NFE2L2CDK2FLT4TLR8
SCHEMBL5340468 0.90 CDK2 (0.42) KEAP1NFE2L2CDK2FLT4TLR8
SCHEMBL5340168 0.89 CDK2 (0.42) KEAP1NFE2L2CDK2FLT4TLR8
SCHEMBL5336999 0.88 TLR8 (0.47) TLR8TLR7EPHX2HTR1AHTR2A
SCHEMBL5348069 0.87 KEAP1 (0.39) KEAP1NFE2L2CDK2FLT4TLR8
SCHEMBL5337292 0.84 KEAP1 (0.38) KEAP1NFE2L2CDK2FLT4L3MBTL1
SCHEMBL5342027 0.82 TLR7 (0.32) TLR8TLR7
SCHEMBL5340187 0.81 CDK2 (0.39) KEAP1NFE2L2CDK2FLT4TLR8
SCHEMBL5335421 0.81 EPHX1 (0.38) EPHX2
SCHEMBL5333237 0.80 TLR8 (0.47) TLR8TLR7HTR1AHTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 KEAP1 820/4885NFE2L2 607/4885CDK2 1026/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP KEAP1 482/4885NFE2L2 1020/4885CDK2 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.